|
|
Research progress on the treatment of arteriosclerosis obliterans of limbs with traditional Chinese medicine |
YE Xuejin1 LI Zhihong1 DENG Baiyang2 |
1.Graduate School, Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530001, China;
2.Department of Hepatobiliary and Peripheral Vascular Surgery, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530000, China |
|
|
Abstract With the rapid development of social economy, changes in diet and lifestyle of huge, lead to obesity is on the rise, the incidence of arteriosclerosis obliterans (ASO) increased year by year, when ASO develops to the middle and late stages, most patients lose the ability to walk normally due to insufficient blood supply to the limbs, and eventually face the choice of high paraplegia. At present, there are no effective methods and drugs, and both surgery and interventional therapy have high costs and the possibility of recurrence is 30%-50%. Therefore, seeking for effective treatment measures is a key problem that needs to be solved urgently. Traditional Chinese medicine has unique advantages in the treatment of limb ischemic vascular diseases, so it is particularly urgent to strengthen the research on the treatment of ASO by traditional Chinese medicine, especially in the field of surgery of traditional Chinese medicine, and to find a research that can effectively treat ASO by utilizing modern research and traditional Chinese medicine technology. This paper aims to comprehensively summarize the current situation and treatment prospect in this field, so as to provide theoretical basis for the future surgical treatment of ASO in traditional Chinese medicine, so as to better improve the clinical effect.
|
|
|
|
|
[1] Wiltz-James LM,Foley J. Hospital Discharge Teaching for Patients with Peripheral Vascular Disease [J]. Crit care nurs clin North Am,2019,31(1):91-95.
[2] Wu W,Shan Z,Wang R,et al. Overexpression of miR-223 inhibits foam cell formation by inducing autophagy in vascular smooth muscle cells [J]. Am J Transll Res,2019,11(7):4326-4336.
[3] 吴华东,沈健,陈诚.血管腔内治疗高龄下肢动脉硬化闭塞症患者的疗效[J].浙江创伤外科,2019,24(6):1192-1194.
[4] 王馥声.动脉硬化性闭塞症的中医证候学研究及临床应[D].北京:北京中医药大学,2007.
[5] 郭娴.吕培文教授学术思想、临床经验总结及应用调和气血法治疗动脉硬化闭塞症临床研究[D].北京中医药大学,2016.
[6] 孙吉峰,范海静,刘玮,等.下肢动脉硬化闭塞症介入术后狭窄治疗效果研究[J].中国预防医学杂志,2019,20(10):992-995.
[7] 谢诗情,程文静,祝骥,等.动脉粥样硬化机制的研究进展[J].世界复合医学,2016,2(3):85-90.
[8] 陈婵,陈长勋.高血压引起动脉硬化的发病机制及其中医药防治[J].中成药,2012,34(1):117-125.
[9] 寇威,刘蔚,孟庆江,等.中药泡足联合前列地尔治疗糖尿病下肢动脉硬化闭塞症临床观察[J].光明中医,2019, 34(21):3329-3330.
[10] 徐小妹,林文津,张亚敏,等.泽泻汤降脂作用与肠道微生态的相关性探讨[J].中国实验方剂学杂志,2017,23(3):116-121.
[11] 宋飞,赵诚,曹永兵,等.软坚清脉颗粒含药血清对血管内皮细胞缺氧损伤的保护作用[J].上海中医药大学学报,2019,33(2):73-79.
[12] 蔡小蓉,杨建云,肖炳坤,等.茵陈五苓散的药理及临床研究进展[J].中国临床药理学杂志,2017,33(9):857-860.
[13] 张欣,张静,葛建立,等.芪黄疽愈方联合前列地尔注射液治疗下肢动脉硬化闭塞症随机对照研究[J].中国中西医结合杂志,2019,39(12):1457-1462.
[14] 秦合伟,李彦杰,任锟,等.基于TLR3/TLR9介导巨噬细胞自噬/极化效应探讨血管软化丸抗AS的作用机制[J].辽宁中医杂志,2019,46(1):156-160,225.
[15] 陈博.软坚散结配方对颈动脉粥样硬化斑块干预作用机制的研究[D].武汉:湖北中医药大学,2014.
[16] 何泽生,张美花,黄仕任,等.蠲脉Ⅰ号对兔动脉硬化血液流变学和血脂的影响[J].广西医学,2014,36(1): 56-58.
[17] 侯俊杰,李大勇,李世征,等.加味阳和汤治疗寒凝血瘀证下肢动脉硬化闭塞症的临床疗效及对血清ET-1、NO水平变化的影响[J].中华中医药学刊,2019,37(9):2093-2097.
[18] 黄浪浪,徐驲,刘中勇.下肢动脉硬化闭塞症的中西医研究进展[J].江西中医药大学学报,2018,30(5):121-124.
[19] 张幼雯.基于数据挖掘技术糖尿病肢体动脉闭塞症用药规律研究[D].济南:山东中医药大学,2011.
[20] 胡满香,李浩杰,李晓东,等.穴位注射联合注射用血栓通治疗下肢动脉硬化闭塞症60例疗效观察[J].河北中医,2014,36(6):869-871.
[21] 曾淋.论中药泡脚于早期糖尿病周围神经病变患者的重要性[J].大众科技,2015,17(2):86-87,104.
[22] 贾慧.溃疡油干预糖尿病溃疡愈合的实验及临床研究[D].北京:北京中医药大学,2016.
[23] 王文霞.清热解毒外敷治法治疗感染性糖尿病足的临床研究[D].北京:北京中医药大学,2006.
[24] 李国林.TASCⅡC/D型股腘动脉硬化闭塞症腔内治疗疗效分析[D].广州:广州医科大学,2018. |
|
|
|